SCHEMBL3480989

SCHEMBL3480989

C=C1CC2C=CC1C2.CC=C1CC2C=CC1C2

nearest known ligand 0.79

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6248152 1.00 HSD17B10 (0.79) HSD17B10
Ethylene SCHEMBL11522064 0.89 HSD17B10 (0.92) HSD17B10
SCHEMBL31490441 0.89
SCHEMBL18277428 0.89
Propene SCHEMBL16439952 0.87 HSD17B10 (0.88) HSD17B10
Iodide SCHEMBL11882843 0.87 HSD17B10 (0.96) HSD17B10
Butadiene SCHEMBL10731965 0.85 HSD17B10 (0.85) HSD17B10
Propene SCHEMBL1661040 0.85 HSD17B10 (0.85) HSD17B10
Propene SCHEMBL2322954 0.85 HSD17B10 (0.85) HSD17B10
Propene SCHEMBL1022915 0.85 HSD17B10 (0.85) HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767376-B2 Catalyst mixture ARLANXEO NETHERLANDS B.V. (NL) 2023-09-26 US claimed
US-11578148-B2 Metal complex comprising amidine and thiophene fused cyclopentadienyl ligands ARLANXEO NETHERLANDS B.V. 2023-02-14 US claimed
US-20220056162-A1 CATALYST MIXTURE ARLANXEO NETHERLANDS B.V. (NL) 2022-02-24 US claimed
EP-3732183-B1 METAL COMPLEX COMPRISING AMIDINE AND THIOPHENE FUSED CYCLOPENTADIENYL LIGANDS Arlanxeo Netherlands Bv (NL) 2021-10-20 EP claimed
EP-3853265-A1 CATALYST MIXTURE Arlanxeo Netherlands B.V. (NL) 2021-07-28 EP claimed
US-20210087305-A1 METAL COMPLEX COMPRISING AMIDINE AND THIOPHENE FUSED CYCLOPENTADIENYL LIGANDS ARLANXEO NETHERLANDS B.V. (NL) 2021-03-25 US claimed
EP-3781582-A1 METAL COMPLEX COMPRISING AMIDINE AND INDOLE FUSED CYCLOPENTADIENYL LIGANDS Arlanxeo Netherlands B.V. (NL) 2021-02-24 EP claimed
EP-3732183-A1 METAL COMPLEX COMPRISING AMIDINE AND THIOPHENE FUSED CYCLOPENTADIENYL LIGANDS Arlanxeo Netherlands B.V. (NL) 2020-11-04 EP claimed
EP-2857423-B1 Catalyst system Arlanxeo Netherlands Bv (NL) 2020-09-16 EP claimed
EP-3334768-B1 CATALYST SYSTEM Arlanxeo Netherlands Bv (NL) 2020-05-27 EP claimed
US-20160115265-A1 METAL COMPLEX WITH A LEWIS BASE LIGAND THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) 2016-04-28 US claimed
EP-2816050-B1 Bimetallic complex comprising cyclopentadienyl and amidine ligands LANXESS ELASTOMERS BV (NL) 2016-04-27 EP claimed
WO-2016041818-A1 METAL COMPLEX COMPRISING AMIDINE AND SUBSTITUTED CYCLOPENTADIENYL LIGANDS LANXESS ELASTOMERS B.V. (NL) 2016-03-24 WO claimed
WO-2015052184-A1 CATALYST SYSTEM LANXESS ELASTOMERS B.V. (NL) 2015-04-16 WO claimed
EP-2857423-A1 Catalyst system Lanxess Elastomers B.V. (NL) 2015-04-08 EP claimed
EP-2816050-A1 Bimetallic complex comprising cyclopentadienyl and amidine ligands Lanxess Elastomers B.V. (NL) 2014-12-24 EP claimed
WO-2014202644-A1 BIMETALLIC COMPLEX COMPRISING CYCLOPENTADIENYL AND AMIDINE LIGANDS LANXESS ELASTOMERS B.V. (NL) 2014-12-24 WO claimed
EP-2801578-A1 Metal complex with a bridged cyclopentadienyl amidine ligand Lanxess Elastomers B.V. (NL) 2014-11-12 EP claimed
EP-2801579-A1 Metal complex with a Lewis base ligand Lanxess Elastomers B.V. (NL) 2014-11-12 EP claimed
US-7713539-B2 Medical devices containing radiation resistant block copolymer BOSTON SCIENTIFIC SCIMED, INC. (US) 2010-05-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087305-A1 METAL COMPLEX COMPRISING AMIDINE AND THIOPHENE FUSED CYCLOPENTADIENYL LIGANDS AP3M1, AP2M1, AP1M1 HSD17B10 4671/4885
US-20160115265-A1 METAL COMPLEX WITH A LEWIS BASE LIGAND CD81, LETM1, ANTXR2 HSD17B10 3961/4885
US-11578148-B2 Metal complex comprising amidine and thiophene fused cyclopentadienyl ligands AP3M1, AP2M1, AP1M1 HSD17B10 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.